about
Limitations of medical research and evidence at the patient-clinician encounter scale2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaPrescription and comorbidity screening following consultation for acute gout in primary care.Health care utilization in patients with gout: a prospective multicenter cohort studyFacilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative studyReassessing serum urate targets in the management of refractory gout: can you go too low?A national survey of Veterans Affairs rheumatologists for relevance of quality of care indicators for gout management.2011 recommendations for the diagnosis and management of gout and hyperuricemia.The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout.Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia.Patients and providers view gout differently: a qualitative study.Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study.Gout, urate-lowering therapy, and uric acid levels among adults in the United StatesComparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.Gout and the risk of dementia: a nationwide population-based cohort study.Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists.Diagnosis and Treatment of Acute Gout at a University Hospital Emergency Department.A cross-sectional internet-based patient survey of the management strategies for gout.Trends in Emergency Department Visits and Charges for Gout in the United States between 2006 and 2012.Impact of deficits in gout care on hospitalizations."It's complicated" - talking about gout medicines in primary care consultations: a qualitative study.Risk of end-stage renal disease associated with gout: a nationwide population study.Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes.Racial and gender disparities among patients with gout.Gout-related inpatient utilization: a study of predictors of outcomes and time trends.Imaging appearances in goutModifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare systemPrimary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaireA Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical TrialQuality of life and quality of care for patients with gout.Gout in the Hmong in the United States.Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study.Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout.Emerging therapies for gout.Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.Management of gout in general practice--a systematic review.Febuxostat for the chronic management of hyperuricemia in patients with gout.Rheumatologists' perception of systemic lupus erythematosus quality indicators: significant interest and perceived barriers.Prevalence of comorbidities and management of gout in a tropical city in Australia.
P2860
Q24282606-FEB5B253-AB92-494F-948A-EC99B3C0055BQ24612292-3F470CF4-2B3A-4C8A-97BF-97944AF08548Q30888155-3EB3A468-4229-48A8-9481-F6229A33CD48Q33750100-4DE7DEE7-9064-438C-BD46-24A4CD6787B2Q33766810-A9AECE5A-F3C4-49E7-B559-7D7595D76EDFQ34061506-075EA271-C85E-446B-8D2D-AF80697A371BQ34143160-0FD568F8-402C-4CF7-BE8F-2CFF9CC31A70Q34250995-6BDBE667-DA60-490D-875C-A9CC0C92C2CCQ34502543-15F03E0A-2D86-4FCA-82BB-5ADCCB90A896Q34657910-1E8AFA28-D66B-4756-A2C9-F181276A543AQ35026721-5A6DEC9B-E173-4E3F-9FE2-C3B40CE3724EQ35099038-45C43BEB-3DEF-4470-9FF7-36053B5B00FBQ35126040-F752D17B-9ABF-4D90-9615-1258A4FCEC21Q35186048-F3ECD2A7-0BA2-41FB-8E43-D31BBD18E869Q35595259-31E3B237-305D-466A-A10D-3B42452A1F22Q35658728-CC1CAB6E-2098-4C57-AA43-4917282E14B2Q35746133-E9681912-472D-45C5-8F86-1719FD626E7DQ35763568-EBCAB990-68C3-4B28-8410-F67C0CA032C7Q35941652-E52AF2CE-51A2-47E1-93F2-21B82B3470FAQ36037558-6B424C3F-970F-421D-A890-C43BE428A0F8Q36041293-E841798B-C6D2-48C5-8FF8-DF3B47504F32Q36108109-80E556A8-A4CC-4F63-B089-6AFA7276EDF6Q36245837-39EEDECC-DEA9-4EFF-BC9A-084F3D149579Q36306524-D59D3F2F-51CB-46B2-9EF5-CDF3004F3AC8Q36533940-933420C0-2E4E-4B7F-991F-7BC9359DCE36Q36639088-1ADA3A2F-2A8B-49E6-934B-F93A67F9787AQ36752751-3DEBEA90-56EA-44D8-B74C-BA50A309650FQ37041741-F7272230-65E1-448A-8F2F-28895393447EQ37090059-688A2E09-7D33-49D2-81A3-13240E180E61Q37191351-4A6BCA42-602F-4A79-9463-83E7C29D5630Q37373602-0738DDEF-E60A-4F52-84EF-BC2667C373E5Q37383715-C58A17EE-CDDD-4FE1-B69B-4C92764A835FQ37516253-ACEC3576-94EF-495C-BB59-9C256330F99DQ37702650-CA787FC3-27B4-4989-B211-3CADD9797A13Q38057761-5776AE8C-3B4E-4868-B8F5-AD134EBBFECDQ38123116-8FC15A9F-E559-484B-89BF-9492B51722D2Q38249921-6A0A7D04-B006-4640-B4CD-5C451BABD031Q38760404-DBDE8673-3C3C-4CD7-B756-57EC298D1F52Q38791752-8A19F2AB-F1B5-4AD4-9976-837BC30BEDB3Q38988025-152C2C77-7B79-46FD-B404-EF0960E461EE
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Quality of care for gout in the US needs improvement.
@en
type
label
Quality of care for gout in the US needs improvement.
@en
prefLabel
Quality of care for gout in the US needs improvement.
@en
P2860
P356
P1476
Quality of care for gout in the US needs improvement.
@en
P2093
James S Hodges
Steven M Asch
P2860
P304
P356
10.1002/ART.22767
P577
2007-06-01T00:00:00Z